Cargando…

Multiple Sclerosis Treatment and Melanoma Development

Therapy of multiple sclerosis (MS) with disease-modifying agents such as natalizumab or fingolimod has been associated with the development of cutaneous melanoma. Here we briefly revise literature data and report of a case of a 48-year old woman who developed a melanoma and several atypical naevi af...

Descripción completa

Detalles Bibliográficos
Autores principales: Carbone, Maria Luigia, Lacal, Pedro Miguel, Messinese, Serena, De Giglio, Laura, Pozzilli, Carlo, Persechino, Severino, Mazzanti, Cinzia, Failla, Cristina Maria, Pagnanelli, Gianluca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216218/
https://www.ncbi.nlm.nih.gov/pubmed/32331328
http://dx.doi.org/10.3390/ijms21082950
_version_ 1783532368033742848
author Carbone, Maria Luigia
Lacal, Pedro Miguel
Messinese, Serena
De Giglio, Laura
Pozzilli, Carlo
Persechino, Severino
Mazzanti, Cinzia
Failla, Cristina Maria
Pagnanelli, Gianluca
author_facet Carbone, Maria Luigia
Lacal, Pedro Miguel
Messinese, Serena
De Giglio, Laura
Pozzilli, Carlo
Persechino, Severino
Mazzanti, Cinzia
Failla, Cristina Maria
Pagnanelli, Gianluca
author_sort Carbone, Maria Luigia
collection PubMed
description Therapy of multiple sclerosis (MS) with disease-modifying agents such as natalizumab or fingolimod has been associated with the development of cutaneous melanoma. Here we briefly revise literature data and report of a case of a 48-year old woman who developed a melanoma and several atypical naevi after sub sequential treatment with natalizumab (1 year) and fingolimod (7 years). By immunohistochemistry we observed the presence of T cells and leukocyte infiltration as well as of vascular endothelial growth factor (VEGF)-A expression in the patient melanoma biopsy. Then, we analyzed proliferation, migration and VEGF-A expression in three melanoma cell lines and found out that both natalizumab and fingolimod inhibited tumor cell proliferation but promoted or blocked cell migration depending on the cell line examined. VEGF-A secretion was augmented in one melanoma cell line only after fingolimod treatment. In conclusion, our in vitro data do not support the hypothesis of a direct action of natalizumab or fingolimod on melanoma progression but acting on the tumor microenvironment these treatments could indirectly favor melanoma evolution.
format Online
Article
Text
id pubmed-7216218
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72162182020-05-22 Multiple Sclerosis Treatment and Melanoma Development Carbone, Maria Luigia Lacal, Pedro Miguel Messinese, Serena De Giglio, Laura Pozzilli, Carlo Persechino, Severino Mazzanti, Cinzia Failla, Cristina Maria Pagnanelli, Gianluca Int J Mol Sci Case Report Therapy of multiple sclerosis (MS) with disease-modifying agents such as natalizumab or fingolimod has been associated with the development of cutaneous melanoma. Here we briefly revise literature data and report of a case of a 48-year old woman who developed a melanoma and several atypical naevi after sub sequential treatment with natalizumab (1 year) and fingolimod (7 years). By immunohistochemistry we observed the presence of T cells and leukocyte infiltration as well as of vascular endothelial growth factor (VEGF)-A expression in the patient melanoma biopsy. Then, we analyzed proliferation, migration and VEGF-A expression in three melanoma cell lines and found out that both natalizumab and fingolimod inhibited tumor cell proliferation but promoted or blocked cell migration depending on the cell line examined. VEGF-A secretion was augmented in one melanoma cell line only after fingolimod treatment. In conclusion, our in vitro data do not support the hypothesis of a direct action of natalizumab or fingolimod on melanoma progression but acting on the tumor microenvironment these treatments could indirectly favor melanoma evolution. MDPI 2020-04-22 /pmc/articles/PMC7216218/ /pubmed/32331328 http://dx.doi.org/10.3390/ijms21082950 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Carbone, Maria Luigia
Lacal, Pedro Miguel
Messinese, Serena
De Giglio, Laura
Pozzilli, Carlo
Persechino, Severino
Mazzanti, Cinzia
Failla, Cristina Maria
Pagnanelli, Gianluca
Multiple Sclerosis Treatment and Melanoma Development
title Multiple Sclerosis Treatment and Melanoma Development
title_full Multiple Sclerosis Treatment and Melanoma Development
title_fullStr Multiple Sclerosis Treatment and Melanoma Development
title_full_unstemmed Multiple Sclerosis Treatment and Melanoma Development
title_short Multiple Sclerosis Treatment and Melanoma Development
title_sort multiple sclerosis treatment and melanoma development
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216218/
https://www.ncbi.nlm.nih.gov/pubmed/32331328
http://dx.doi.org/10.3390/ijms21082950
work_keys_str_mv AT carbonemarialuigia multiplesclerosistreatmentandmelanomadevelopment
AT lacalpedromiguel multiplesclerosistreatmentandmelanomadevelopment
AT messineseserena multiplesclerosistreatmentandmelanomadevelopment
AT degigliolaura multiplesclerosistreatmentandmelanomadevelopment
AT pozzillicarlo multiplesclerosistreatmentandmelanomadevelopment
AT persechinoseverino multiplesclerosistreatmentandmelanomadevelopment
AT mazzanticinzia multiplesclerosistreatmentandmelanomadevelopment
AT faillacristinamaria multiplesclerosistreatmentandmelanomadevelopment
AT pagnanelligianluca multiplesclerosistreatmentandmelanomadevelopment